ClinicalTrials.gg
SuspendedNCT04846036Updated Jan 10, 2025

The KHENERGYC Study

A Phase 2 interventional study of Sonlicromanol and Placebo in Mitochondrial Diseases, Mitochondrial DNA tRNALeu(UUR) m.3243A<G Mutation and MELAS, sponsored by Khondrion BV. Suspended at 1 site in Netherlands. Open to participants aged 0 Years to 17 Years. Per ClinicalTrials.gov, last updated 2025-01-10.

Sponsored by Khondrion BV · Phase 2, Interventional, and Treatment

How we know

Why this study was suspended
Strategic company decision - not related to safety concerns

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
0 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 11 studies in Mitochondrial Diseases with a site in Netherlands — 2 open to participants now, 3 under way, 1 of them phase 3. Mitochondrial Diseases · Netherlands.

Planned enrollment
6th of 11
24 · median 24
Started
2021
with 1 other
Phase 2
5 of 11
1 open now
Registered
6th of 11
by date
Lead sponsor
5 of 11
Khondrion BV

Among the 11 studies in Mitochondrial Diseases with a site in Netherlands, this one is the 6th largest by planned enrollment, is one of 2 that started in 2021, is one of 5 in phase 2, and was the 6th registered.

Mitochondrial Diseases

189 studies on the registry are indexed under Mitochondrial Diseases; 60 are open to participants now.

Browse Mitochondrial Diseases studies →

Open to participants now

2 of the 11 studies in Mitochondrial Diseases with a site in Netherlands are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 41 Mitochondrial Diseases studies recruiting now, 20 (49%) set no upper age limit and 14 (34%) stop at 75 or younger; 19 take children under 18; 17 take healthy volunteers.

This study: 0 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Mitochondrial Diseases with a site in Netherlands, or all of them as a file.
02

Study summary

This a randomized placebo controlled, double-blind phase II study to explore the pharmacokinetics, safety and efficacy of sonlicromanol in children (from birth to 17 years) with genetically confirmed mitochondrial disease of which the gene defect is known to decrease one or more oxidative phosphorylation system enzymes and who suffer from motor symptoms ("KHENERGYC").

Read the detailed description

Mitochondrial Diseases (MD) are rare progressive, multi-system, often early onset and fatal disorders affecting both children and adults. Despite advances in the understanding of mitochondrial disorders, treatment options are extremely limited and, to date, largely supportive. Therefore, there is an urgent need for novel treatments. Sonlicromanol (KH176) is an orally bio-available small molecule under development for the treatment of these disorders. The current study will explore the pharmacokinetics, safety and efficacy of sonlicromanol in children (from birth to 17 years) with genetically confirmed mitochondrial disease of which the gene defect is known to decrease one or more oxidative phosphorylation system enzymes and who suffer from motor symptoms.

The primary objective of the study is to evaluate the effect of sonlicromanol on motor symptom severity in children with genetically confirmed mitochondrial disease affecting oxidative phosphorylation during a 6 month treatment period (GMFM).

The trial consists of 2 phases, with the main phase being a randomized placebo controlled, double-blind, phase II parallel group study to explore the efficacy and safety of sonlicromanol in twenty-four (24) children with mitochondrial disease and motor symptoms,.

The first phase is an adaptive PharmacoKinetics (PK) study with 4 days treatment (to expected steady state in most subjects) in the following age-groups: birth - 1 year, 1-2 years, 2- 6 years, 6-12 years, and 12 - 17 years. An age group should have at least 3 subjects before being analysed. Subjects will take 4 days of open-label sonlicromanol orally at the anticipated adult-equivalent dose. After completion of enrolment in an age group, the PK data from that age group will be analysed to confirm the adult-equivalent dose that will be used thereafter in the second phase of the trial. Older age groups will be studied before younger age groups.

In the second phase subjects will be randomized (by age group) over 2 groups. Group 1 will receive an adult-equivalent dose of sonlicromanol twice daily orally for 26 weeks. Group 2 will receive matching placebo twice daily for 26 weeks. A final follow-up visit is scheduled 2 weeks after the intake of the last dose of the treatment period.

Duration of Subject Participation:

The overall study duration of the trial for a eligible subject is estimated to be approximately 7 months, consisting of up to 4 weeks screening, 26 weeks (6 months) of treatment and 2 week post-treatment follow-up. At the end of the study treatment all participants will be offered to continue treatment with sonlicromanol during a open label extension (OLE) trial for 12 months.

03

Conditions studied

  • Mitochondrial Diseases
  • Mitochondrial DNA tRNALeu(UUR) m.3243A<G Mutation
  • MELAS
  • Subacute Necrotizing Encephalomyelopathy

Keywords

  • KH176
  • Sonlicromanol
  • MELAS
  • Leigh syndrome
  • Oxidative phosphorylation (oxphos)
  • Phase II
04

Who can participate

Ages eligible
0 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age between 0 months and 17 years
  2. Genetically confirmed mitochondrial disease, of which the gene defect is known to decrease one or more oxidative phosphorylation system enzymes and who suffer from motor symptoms, based on investigator judgement
  3. Abnormal gross motor function and/or presence of at least one motor symptom (hypotonia, decreased muscle strength, ataxia, dystonia, chorea and/or spasticity) based on investigator judgement
  4. Before enrollment in the adaptive PK phase and before randomization into the double-blind placebo-controlled phase: Gross Motor Function Measure-88 (GMFM-88) Total Score ≤96%
  5. Before enrollment in the adaptive PK phase and before randomization into the double-blind placebo-controlled phase: International Paediatric Mitochondrial Disease Scale IPMDS Score ≥10
  6. Stable disease symptoms since the previous routine control visit (consistent with a score of "stable" on the item "disease course since previous IPMDS" of the IPMDS) in the opinion of the investigator.
  7. Written informed (patient/parental/caregiver) consent, able and willing to comply with the study requirements of the study protocol.
  8. Women of must be willing to use highly effective methods during the entire study, i.e. combined (estrogen and progestogen containing) oral, intravaginal or transdermal hormonal contraception associated with inhibition of ovulation; oral, injectable, or or implantable progestogen-only hormonal contraception associated with inhibition of ovulation; use of an intrauterine device; an intrauterine hormone releasing system, bilateral tubal occlusion and vasectomy of the partner. Any hormonal contraception method must be supplemented with a barrier method (preferably male condom). Vasectomised partner is considered a highly effective birth control method provided that partner is the sole sexual partner of the subject and that the vasectomised partner has received medical assessment of the surgical success. Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments. Reliability of sexual abstinence needs to be evaluated in in relation to the duration of the clinical trial and the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.

Note 1: Natural family planning methods, female condom, cervical cap or diaphragm are not considered adequate contraceptive methods in the context of this study.

Note 2: To be considered not of childbearing potential, potential female subjects must have been surgically sterilized (bilateral tubal ligation, hysterectomy or bilateral oophorectomy) for at least 6 months prior to Screening.

Note 3: KH176 has been shown non-genotoxic judged from the Ames test, Chromosomal Aberration test and in vivo Micronucleus test. Moreover, appreciable systemic exposure from the exposure to (\~2.5 mL) semen is extremely unlikely. However, until reproductive toxicology studies have confirmed that KH176 does not adversely affect normal reproduction in adult males and females, as well as causing developmental toxicity in the offspring, the following contraceptive precautions must be adhered to:

  • male subjects with female partners of childbearing potential must be willing to use condoms during the entire study.
  • female partners of childbearing potential of male subjects must be willing to use adequate contraceptive methods during the entire study, i.e., a hormonal contraceptive method (pill, vaginal ring, patch, implant, injectable, hormone-medicated intrauterine device) or an intrauterine device.

Exclusion criteria

Exclusion criteria:

  1. Surgery of the gastro-intestinal tract with removal of piece(s) of stomach, duodenum or jejunum that might interfere with absorption. Feeding through gastrostomy tube is however allowed.
  2. Treatment with an product within 3 months or 5 times the half-life of the investigational product (whichever is longer) prior to the first dose of the study medication.
  3. cardiovascular disease or risk factors for arrythmia:

    1. Abnormal (including exceeding the 95th percentile for the age- and sex-dependent QTc interval (https://www.qtcalculator.org) and/or abnormal structural or functional 2D ECHO
    2. Systolic Blood Pressure (SBP) above the 95th percentile for the sex, age group and height percentile at screening or baseline on single measurement (see appendix 1)
    3. History of acute or chronic heart failure, (family) history of unexplained syncope or congenital long and short QT syndrome or sudden death
    4. Hyperkalemia or hypokalemia; hypomagnesemia or hypermagnesemia; hypocalcemia or hypercalcemia (local laboratory normal values; to be judged by investigator)
  4. Clinically relevant abnormal laboratory results:

    1. (ASAT) or alanine aminotransferase (ALAT) > 3 times (ULN), or > 3 x ULN. If a patient has ASAT or ALAT > 3 x ULN but \< 3.5 x ULN, re-assessment is allowed at the investigator's discretion.
    2. Estimated below age-appropriate limits (according to the formula: 40.9* ((1.8 / Cystatine C)0.93):

      \< 2 months: \< 25 ml/min/1.73 m2 2 months to 1 year: \< 35 ml/min/1.73 m2 > 1 year: \< 60 ml/min/1.73 m2

    3. All other clinically relevant parameters at screening or baseline as judged by the investigator
  5. History of or idiosyncrasy to any of the components of the investigational product.
  6. Medical history of drug abuse (illegal drugs such as cannabinoids, amphetamines, cocaine, opiates or problematic use of prescription drugs such as benzodiazepines, opiates).
  7. The use of any of the following medication and/or supplements within 4 weeks or 5 times the half-life (whichever is longer) prior to the first dosing of the study medication:

    1. (multi)vitamins, co-enzyme Q10, Vitamin E, riboflavin, and antioxidant supplements (including, but not limited to idebenone/EPI-743, mitoQ); unless stable for at least one month before first dosing and remaining stable throughout the study.
    2. any medication negatively influencing mitochondrial functioning (including but not limited to valproic acid, glitazones, statins, anti-virals, amiodarone, and non-steroidal anti- inflammatory drugs (NSAIDs)), unless stable for at least one month before first dosing and remaining stable throughout the study.

      Note: thus, mitoQ and any medication negatively influencing mitochondrial functioning are allowed as long as the dose has been stable for at least one month prior to first dosing and remains stable throughout the study.

    3. any strong Cytochrome P450 (CYP)3A4 inhibitors (all 'conazoles-anti-fungals', antivirals, grapefruit).
    4. strong inducers (including HIV antivirals, carbamazepine, phenobarbital, phenytoin, rifampicin, St. John's wort, pioglitazone, troglitazone).
    5. any medication known to affect cardiac repolarisation, unless the QTc interval at screening is normal during stable treatment for a period of two weeks, or 5 half-lives of the medication and its major metabolite(s), whichever period is the shortest (all anti-psychotics, several anti-depressants: nor- / amitriptyline, fluoxetine, anti-emetics: domperidone (Motilium®), granisetron, ondansetron).
    6. any medication metabolised by CYP3A4 with a narrow therapeutic width.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Sonlicromanol

    Paediatric-equivalent dose (as determined by Physiologically Based Pharmacokinetics (PBPK) modelling and the results of the Adaptive PK study) of sonlicromanol twice daily administered as an oral liquid for 26 weeks

    Drug: Sonlicromanol

  • Placebo comparator
    Placebo

    Matching placebo twice daily orally for 26 weeks

    Drug: Placebo

Interventions

  • DrugTroloxStudies of TroloxTrolox pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Oral administration of sonlicromanol twice daily

    Also known as: KH176

  • DrugPlacebo

    Oral administration of matching placebo twice daily

06

What researchers measure

Primary outcomes

  1. Motor Symptom Severity as assessed with the Gross Motor Function Measure-88 (GMFM-88)

    Changes from baseline to each assessment of the GMFM-88.The GMFM-88 consists of 88 questions and assesses motor function in 5 domains (lying and rolling; sitting; crawling and kneeling; standing; walking, running, and jumping). 4-point scoring system for each item, item scores ranges from 0-3. Higher scores denote better performance. Scaled score indicates the percentage of total score. Total score ranges from 0-100%

    Time frame: Baseline (Day 1), week 6, week 13, week 27, week 29

Secondary outcomes

  1. Fine manual motor skills as assessed with the 9 Hole Peg Test (NHPT)

    Changes from baseline to each assessment of the NHPT. The NHPT examines the fine hand motor skills by assessing the speed of movement of the hand.The fastest time of 2 attempts is recorded for the dominant hand as well as the non-dominant hand. When the maximum time is reached (50 seconds) the number of transported rods is counted (maximum = 18; minimum = 0). Faster times (in sec) and higher number of rods denote better performance.

    Time frame: Baseline (Day 1), week 6, week 13, week 27, week 29

  2. Spasticity as assessed with the Modified Tardieu Scale for spasticity (MTS)

    Changes from baseline to each assessment of the MTS. The MTS quantifies spasticity by assessing the muscle's response to stretch applied at three specified velocities (as slow as possible; speed of limb falling under gravity; moving as fast as possible) and rating the intensity and duration of the muscle reaction to stretch and the joint angle. The quality of the muscle reaction (spasticity grade) is scored on a 5-grade scale (range: 'No resistance throughout the course of the movement' to 'Joint immovable'). Lower scores denote better performance. The Spasticity Angle X is the difference between the angles of arrest at slow speed and of catch-and release or clonus at fast speed; the Spasticity Grade Y is an ordinal variable that grades the intensity (gain) of the muscle reaction to fast stretch. The outcome parameter of angle (in degrees, range: 0-180 degrees) can only be determined with spasticity grade 2 and higher.

    Time frame: Baseline (Day 1), week 6, week 13, week 27, week 29

  3. Dystonia as assessed with Dystonia (Barry-Albright Dystonia scale (BAD)

    Changes from baseline to each assessment of the BAD. The BAD assesses dystonia in eight body regions: eyes, mouth, neck, trunk, and the four extremities. Dystonia is scored as none (0), slight (1), mild (2), moderate (3), or severe (4). Individual scores for each region are added for a total score. total score ranging from 0-32. A higher score denotes worse outcome.

    Time frame: Baseline (Day 1), week 6, week 13, week 27, week 29

  4. Ataxia as assessed with the Scale for the Assessment and Rating of Ataxia (SARA)

    Changes from baseline to each assessment of the SARA. The SARA is a semi- quantitative assessment of a range of different impairments in cerebellar ataxia. The scale is an 8-item based scale related to gait, stance, sitting, speech, finger-chase test, nose-finger test, fast alternating movements and heel-shin test. The score ranges from 'no ataxia' (0) to 'most severe ataxia' (40). A higher score denotes worse outcome.

    Time frame: Baseline (Day 1), week 6, week 13, week 27, week 29

  5. Disability as assessed with the PEDI-CAT (Paediatric Evaluation of Disability Inventory (PEDI-CAT)

    Changes from baseline to each assessment of the PEDI-CAT. The PEDI-CAT is a computer adaptive caregiver report which estimates a child's abilities from a minimal number of the most relevant items or from a set number of items within three functional domains: Daily Activities, Mobility, Social/Cognitive, and Responsibility. \<= 30 items per domain. Higher scores denote better performance.

    Time frame: Baseline (Day 1), week 6, week 13, week 27, week 29

  6. Mitochondrial disease signs and symptoms as assessed with the International Paediatric Mitochondrial Disease Scale (IPMDS)

    Changes from baseline to each assessment of the IPMDS. The IPMDS assesses all aspects of mitochondrial disease by exploring three domains: a) 'complaints and symptoms' (23 items), b) 'physical examination' (21 items) and c) 'functional tests' (13 items). The domain and total scores are expressed as the percentage of items which were feasible to perform (maximum = 100%; minimum = 0%. A higher score denotes better performance.

    Time frame: Baseline (Day 1), week 6, week 13, week 27, week 29

  7. Caregiver burden as assessed with the ZARIT-12 Burden scale (ZBI-12)

    Changes from baseline to each assessment of the ZBI-12. The ZBI-12 assesses caregiver perceptions of burden by indicating the extent of burden experienced while providing care to their child. The responses on the scale range from 'not at all' to 'extremely'. Total scores are obtained by summing the item scores, maximum = 48; minimum = 0). higher scores denote higher burden.

    Time frame: Baseline (Day 1), week 6, week 13, week 27, week 29

  8. Quality of life as assessed with the Neurology Quality of life short Form (NeuroQL-SF)

    Changes from baseline to each assessment of the NeuroQL-SF. The Fatigue Short Form Paediatric version is an 8-item score evaluating the perception of fatigue and its impact in daily life activities. Scores on individual items range from 1-5. The total score ranges from 5-40. Higher score denotes worse outcome.

    Time frame: Baseline (Day 1), week 6, week 13, week 27, week 29

  9. Clinician-scored global impression of change (CGIC)

    Changes from baseline to each assessment of the CGIC. The CGIC assesses the clinician's perception of the degree to which patient's illness/symptoms have improved or worsened following intervention using a 7-point Likert scale. Score ranges from 1-7. A higher score denotes worsening of symptoms.

    Time frame: Baseline (Day 1), week 6, week 13, week 27, week 29

  10. Patient/Caregiver scored global impression of change (PGIC)

    Changes from baseline to each assessment of the PGIC. The PGIC assesses patient's/caregiver's perception of the degree to which patient's illness/symptoms have improved or worsened following intervention using a 7-point Likert scale. Score ranges from 1-7. A higher score denotes worsening of symptoms.

    Time frame: Baseline (Day 1), week 6, week 13, week 27, week 29

  11. Patient/Caregiver scored impression of change on patient-identified 3 Most Bothersome Symptoms (MBSA) caused by mitochondrial disease

    Changes from baseline to each assessment of the MBSA. The MBSA assesses patient/caregiver scored impression of the degree to which each of the 3 patient-identified most bothersome symptoms caused by mitochondrial disease have improved or worsened following intervention. Score ranges from 1-7 for each of the symptoms. A higher score denotes worsening of symptoms.

    Time frame: Baseline (Day 1), week 6, week 13, week 27, week 29

  12. Growth as assessed by weight

    Changes from baseline to each assessment of weight in kilogram (Kg)

    Time frame: Baseline (Day 1), week 6, week 13, week 27, week 29

  13. Growth as assessed by height

    Changes from baseline to each assessment of height in centimeters (cm)

    Time frame: Baseline (Day 1), week 6, week 13, week 27, week 29

  14. Growth as assessed by head circumference

    Changes from baseline to each assessment of head circumference in centimeters (cm), for children younger than 3 years only.

    Time frame: Baseline (Day 1), week 6, week 13, week 27, week 29

  15. Growth as assessed by Body Mass Index (BMI)

    Changes from baseline to each assessment of BMI, weight and height will be combined to report BMI in kg/m\^2 children aged 3 years and above

    Time frame: Baseline (Day 1), week 6, week 13, week 27, week 29

  16. Temperature

    Changes from baseline to each assessment of temperature in degree Celsius

    Time frame: Baseline (Day 1), week 6, week 13, week 27, week 29

  17. 10 meter Walk Test (10MWT)

    Changes from baseline to each assessment of the 10MWT. The 10MWT assesses the patients' physical ability to walk/run, the patients' walking speed and stamina. The patient is instructed to walk/run 10 meters and the time is measured while the patient walks the set distance. Faster times (in sec) denotes better performance.

    Time frame: Baseline (Day 1), week 6, week 13, week 27, week 29

Other outcomes

  1. Mortality

    Mortality rate during treatment

    Time frame: Up to 29 weeks

  2. Health Utility Index (HUI)

    Changes from baseline to each assessment of the HUI. The HUI is measuring health status and health-related quality of life (HRQL) on multiple dimensions of health status, including vision, hearing, speech, ambulation/mobility, pain, dexterity, self-care, emotion and cognition and a HRQL score for overall health. Each dimension has 3- 6 levels. Overall HRQL scores range from 0.00 to 1.00. A higher score denotes better quality of life/health.

    Time frame: Baseline (Day 1), week 6, week 13, week 27, week 29

  3. EQ-5D-Y Proxy

    Changes from baseline to each assessment of the EQ-5D-Y. The EQ-5D-5L-Y (proxy 1) measures health in five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 response categories (levels): no problems, slight problems, moderate problems, severe problems and extreme problems. The patient's health state is indicated in a 1-digit number expressing the level selected for that dimension. The digits for the five dimensions are combined into a 5-digit number that describes the patient's health state, ranging from 11111 (having no problems in all dimensions) to 55555 (having extreme problems in all dimensions). A higher score denotes a worse health state.

    Time frame: Baseline (Day 1), week 6, week 13, week 27, week 29

  4. EQ-Visual Analogue Scale (EQ-VAS)

    Changes from baseline to each assessment of the EQ-VAS.The EQ-VAS measures perceived health, ranging from 0 ('The worst health you can imagine') to 100 ('The best health you can imagine'). Range: 0-100, a higher score denotes better health.

    Time frame: Baseline (Day 1), week 6, week 13, week 27, week 29

  5. Overall survival

    Overall survival over 29 weeks

    Time frame: Up to 29 weeks

  6. Palatability of sonlicromanol as assessed with the five level Facial Hedonic Scale (FHS) and Visual Analogue Scale (VAS)

    FHS combined with a 100-point linear visual analogue scale (VAS), with point 0 aligning with the extreme left of the facial prompt used in the FHS and point 100 aligning with the extreme right side of the FHS. The score ranges from 0 -100. A higher score denotes a better outcome/higher palatability.

    Time frame: Day 1

  7. Acceptability of sonlicromanol as assessed by patient/caregiver daily reporting of acceptability.

    The acceptability of sonlicromanol is determined by daily assessment of acceptability by reporting if the subject has 'swallowed the total dose', 'spat out (part of) the dose', or 'refused to take dose'. Total acceptability scores are obtained by summing the number of doses totally swallowed, spat out or refused.

    Time frame: Up to 27 weeks

  8. HbA1c: mmol Glycated Hb per mol Hb

    Changes from baseline to each assessment of HbA1c. Glucose homeostasis / diabetes control

    Time frame: Baseline (Day 1), week 6, week 13, week 27, week 29

  9. Electrocardiogram (ECG): PQ interval (milliseconds)

    Mean and the maximum change from baseline to each assessment in PQ interval.

    Time frame: Baseline (Day 1), week 6, week 13, week 27, week 29

  10. Electrocardiogram (ECG): QRS duration (milliseconds)

    Mean and the maximum change from baseline to each assessment in QRS duration.

    Time frame: Baseline (Day 1), week 6, week 13, week 27, week 29

  11. Electrocardiogram (ECG): T peak - T end interval

    Mean and the maximum change from baseline to each assessment in T peak - T end interval.

    Time frame: Baseline (Day 1), week 6, week 13, week 27, week 29

  12. Electrocardiogram (ECG): QTc

    Mean and the maximum change from baseline to each assessment in QTc.

    Time frame: Baseline (Day 1), week 6, week 13, week 27, week 29

  13. Electrocardiogram (ECG): T wave morphology: peak, symmetry

    Mean and the maximum change from baseline to each assessment in T wave morphology: peak, symmetry.

    Time frame: Baseline (Day 1), week 6, week 13, week 27, week 29

  14. Treatment Emergent Adverse Events (TEAEs)

    Frequency of TEAEs throughout the study period

    Time frame: up to 29 weeks

  15. Systolic Blood Pressure (mmHG)

    Changes from baseline to each assessment in systolic blood pressure (mmHG)

    Time frame: Baseline (Day 1), week 6, week 13, week 27, week 29

  16. Diastolic Blood Pressure (mmHG)

    Changes from baseline to each assessment in diastolic blood pressure (mmHG)

    Time frame: Baseline (Day 1), week 6, week 13, week 27, week 29

  17. Heartrate (Beats Per Minute (BPM))

    Changes from baseline to each assessment Heartrate in beats per minute (BPM)

    Time frame: Baseline (Day 1), week 6, week 13, week 27, week 29

  18. Haematology: Concentration of haemoglobin (Hb) in mmol/L

    Changes from baseline to each assessment visit in haemoglobin (Hb) concentration in mmol/L

    Time frame: Baseline (Day 1), week 6, week 13, week 27, week 29

  19. Haematology: Haematocrit (Ht): Volume of RBC as fraction of total blood volume (L/L).

    Changes from baseline to each assessment visit in haematocrit (Ht) in L/L

    Time frame: Baseline (Day 1), week 6, week 13, week 27, week 29

  20. Haematology: Mean Corpuscular Haemoglobin (MCH) in pg/cell (average mass of Hemoglobin (Hb) per red blood cell (RBC))

    Changes from baseline to each assessment visit in mean corpuscular haemoglobin (MCH) in pg/cell

    Time frame: Baseline (Day 1), week 6, week 13, week 27, week 29

  21. Haematology: Concentration of Mean Corpuscular Haemoglobin Concentration (MCHC) (mmol/L)

    Changes from baseline to each assessment visit in mean corpuscular haemoglobin concentration in mmol/L

    Time frame: Baseline (Day 1), week 6, week 13, week 27, week 29

  22. Haematology: Red Blood Cell Count (RBC) (cell/L)

    Changes from baseline to each assessment visit in Red Blood Cell (RBC) count in cells/L

    Time frame: Baseline (Day 1), week 6, week 13, week 27, week 29

  23. Haematology: MCV Mean Corpuscular Volume of ared blood cells in femtoliter (fL)

    Changes from baseline to each assessment visit in mean corpuscular volume (MCV) of red blood cells in fL

    Time frame: Baseline (Day 1), week 6, week 13, week 27, week 29

  24. Haematology: White Blood Cell (WBC) count (cells/L)

    Changes from baseline to each assessment visit in white blood cell (WBC) count (cells/L)

    Time frame: Baseline (Day 1), week 6, week 13, week 27, week 29

  25. Haematology: white blood cell differential (WBC differential: neutrophils, lymphocytes, monocytes, eosinophils, basophils) count (cells/L)

    Changes from baseline to each assessment visit in WBC differential (neutrophils, lymphocytes, monocytes, eosinophils, basophils) count in cells/L

    Time frame: Baseline (Day 1), week 6, week 13, week 27, week 29

  26. Haematology: Thrombocytes count (cells/L)

    Changes from baseline to each assessment visit in thrombocytes count in cells/L

    Time frame: Baseline (Day 1), week 6, week 13, week 27, week 29

  27. Haematology: Total protein (g/L)

    Changes from baseline to each assessment visit in total protein in g/L

    Time frame: Baseline (Day 1), week 6, week 13, week 27, week 29

  28. Chemistry: Concentration of Alkaline Phosphatase (Units/L (U/L))

    Changes from baseline to each assessment visit in alkaline phosphatase concentration in U/L

    Time frame: Baseline (Day 1), week 6, week 13, week 27, week 29

  29. Chemistry: Concentration of Aspartate Aminotransferase (ASAT) (Units/L (U/L))

    Changes from baseline to each assessment visit in aspartate aminotransferase (ASAT) concentration in U/L

    Time frame: Baseline (Day 1), week 6, week 13, week 27, week 29

  30. Chemistry: Concentration of Alanine Aminotransferase (ALAT) (Units/L (U/L))

    Changes from baseline to each assessment visit in Alanine Aminotransferase (ALAT) concentration in U/L

    Time frame: Baseline (Day 1), week 6, week 13, week 27, week 29

  31. Chemistry: Concentration of gamma-Glutamyl Transferase (gamma-GT) (Units/L (U/L))

    Changes from baseline to each assessment visit in gamma-Glutamyl Transferase (gamma-GT) concentration in U/L

    Time frame: Baseline (Day 1), week 6, week 13, week 27, week 29

  32. Chemistry: Concentration of total bilirubin (umol/L)

    Changes from baseline to each assessment visit in total bilirubin concentration in umol/L)

    Time frame: Baseline (Day 1), week 6, week 13, week 27, week 29

  33. Chemistry: Concentration of urea (mmol/L)

    Changes from baseline to each assessment visit in urea concentration in mmol/L

    Time frame: Baseline (Day 1), week 6, week 13, week 27, week 29

  34. Chemistry: Concentration of creatinine (umol/L)

    Changes from baseline to each assessment visit in creatinine concentration in umol/L

    Time frame: Baseline (Day 1), week 6, week 13, week 27, week 29

  35. Chemistry: Concentration of creatinine kinase (Units/L (U/L))

    Changes from baseline to each assessment visit in creatinine kinase concentration in U/L

    Time frame: Baseline (Day 1), week 6, week 13, week 27, week 29

  36. Chemistry: Concentration of sodium (mmol/L)

    Changes from baseline to each assessment visit in sodium concentration in mmol/L

    Time frame: Baseline (Day 1), week 6, week 13, week 27, week 29

  37. Chemistry: Concentration of potassium (mmol/L)

    Changes from baseline to each assessment visit in potassium concentration in mmol/L

    Time frame: Baseline (Day 1), week 6, week 13, week 27, week 29

  38. Chemistry: Concentration of calcium (mmol/L)

    Changes from baseline to each assessment visit in calcium concentration in mmol/L

    Time frame: Baseline (Day 1), week 6, week 13, week 27, week 29

  39. Chemistry: Concentration of chloride (mmol/L)

    Changes from baseline to each assessment visit in chloride concentration in mmol/L

    Time frame: Baseline (Day 1), week 6, week 13, week 27, week 29

  40. Chemistry: Concentration of lactate (mmol/L)

    Changes from baseline to each assessment visit in lactate concentration in mmol/L

    Time frame: Baseline (Day 1), week 6, week 13, week 27, week 29

  41. Chemistry: Concentration of Thyroid-stimulating Hormone (TSH) (mE/L)

    Changes from baseline to each assessment visit in Thyroid-stimulating Hormone concentration in mE/L

    Time frame: Baseline (Day 1), week 6, week 13, week 27, week 29

  42. Chemistry: Concentration of free Thyroxine (fT4) (pmol/l)

    Changes from baseline to each assessment visit in free Thyroxine (fT4) concentration in pmol/L

    Time frame: Baseline (Day 1), week 6, week 13, week 27, week 29

  43. Chemistry: Concentration of C-reactive protein (CRP) (mg/L)

    Changes from baseline to each assessment in C-reactive protein (CRP) concentration in mg/L

    Time frame: Baseline (Day 1), week 6, week 13, week 27, week 29

  44. Chemistry: Concentration of lipase (U/L)

    Changes from baseline to each assessment in lipase concentration in U/L

    Time frame: Baseline (Day 1), week 6, week 13, week 27, week 29

  45. Chemistry: Concentration of uric acid (mmol/L)

    Changes from baseline to each assessment in uric acid concentration in mmol/L

    Time frame: Baseline (Day 1), week 6, week 13, week 27, week 29

  46. Chemistry: Concentration of phosphate (mmol/L)

    Changes from baseline to each assessment in phosphate concentration in mmol/L

    Time frame: Baseline (Day 1), week 6, week 13, week 27, week 29

  47. Chemistry: Concentration of human serum albumin (g/L)

    Changes from baseline to each assessment in human serum albumin concentration in g/L

    Time frame: Baseline (Day 1), week 6, week 13, week 27, week 29

  48. Chemistry: Concentration of glucose (mmol/L)

    Changes from baseline to each assessment in glucose concentration in mmol/L

    Time frame: Baseline (Day 1), week 6, week 13, week 27, week 29

  49. Chemistry: Concentration of Lipids: cholesterol, triglycerides, low density lipoproteins (LDL), high density lipoproteins (HDL) (mmol/L)

    Changes from baseline to each assessment in Lipids concentration: cholesterol, triglycerides, low density lipoproteins (LDL), high density lipoproteins (HDL) in mmol/L

    Time frame: Baseline (Day 1), week 6, week 13, week 27, week 29

  50. Chemistry: Concentration of amylase (U/L)

    Changes from baseline to each assessment in amylase concentration in U/L

    Time frame: Baseline (Day 1), week 6, week 13, week 27, week 29

  51. Metabolomics: Concentration of Fibroblast Growth factor 15 (FGF-15) (pg/mL)

    Changes from baseline to each assessment in FGF-15 concentration in pg/mL)

    Time frame: Baseline (Day 1), week 27

  52. Metabolomics: Concentration of Growth Differentiation Factor-15 (GDF-15) (pg/mL)

    Changes from baseline to each assessment in GDF-21 concentration (in pg/mL)

    Time frame: Baseline (Day 1), week 27

  53. Pharmacokinetics: Time-to-peak drug plasma concentration (Tmax) (hours)

    Tmax: Time to reach maximum (peak) plasma concentration following drug administration (hours)

    Time frame: Baseline (Day 1), Week 27

  54. Pharmacokinetics: Peak drug concentration (Cmax) (ng/mL)

    Changes from baseline to week 27 in Tmax: Maximum (peak) plasma drug concentration in ng/mL

    Time frame: Baseline (Day1), week 27

  55. Pharmacokinetics: Ctrough (ng/mL)

    Changes from baseline to week 27 in plasma concentration (measured concentration at the end of a dosing interval at steady state in ng/mL

    Time frame: Baseline (Day1), week 27

  56. Pharmacokinetics: AUCinf (h*ng/mL)

    Changes from baseline to week 27i n Area under the plasma concentration time curve from time zero to infinity in h\*ng/mL

    Time frame: Baseline (Day1), week 27

  57. Pharmacokinetics: AUCtau (h*ng/mL)

    Changes from baseline to week 27 in Area under the plasma concentration time curve in h\*ng/mL

    Time frame: Baseline (Day1), week 27

07

Study locations

1 site
  • Radboud University Medical Center
    Nijmegen, Gelderland 6525 EX, Netherlands
08

References and documents

Publications

  • Smeitink J, van Maanen R, de Boer L, Ruiterkamp G, Renkema H. A randomised placebo-controlled, double-blind phase II study to explore the safety, efficacy, and pharmacokinetics of sonlicromanol in children with genetically confirmed mitochondrial disease and motor symptoms ("KHENERGYC"). BMC Neurol. 2022 Apr 27;22(1):158. doi: 10.1186/s12883-022-02685-3. PubMed 35477351 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2021 (actual). Primary completion is estimated for Dec 2025, 58 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2021
First posted
Apr 15, 2021
StartActual
Feb 1, 2021
Primary completionEst.
Dec 1, 2025
CompletionEst.
Dec 1, 2025
Last update
Jan 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04846036
Lead sponsor
Khondrion BV
Collaborators
Julius Clinical, ProPharma Group, Europees Fonds voor Regionale Ontwikkeling (EFRO), Ardena, Certara
Responsible party
Sponsor
First posted
Apr 15, 2021
Start date
Feb 1, 2021
Primary completion
Dec 1, 2025 (estimated)
Completion
Dec 1, 2025 (estimated)
Last update
Jan 10, 2025

Study contacts

Lonneke de Boer, MD
principal investigator · Radboud University Medical Center Nijmegen, Netherlands

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is suspended, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trolox

Start the discussion